Geron Reviews

7 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
Geron Director, President & CEO John A. Scarlett
John A. Scarlett
1 Rating

Geron Awards and Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Menlo Park, CA
Size 50 to 149 Employees
Founded 1990
Type Company - Public (GERN)
Industry Biotech & Pharmaceuticals
Revenue $1 to $5 million (CAD) per year

Geron is working to get important things into our thick heads -- more specifically, it is developing a compound able to penetrate the blood-brain barrier that otherwise keeps potentially valuable drugs out of the brain. The company's research and development is targeting viable therapies for cancer, injury, and degenerative diseases. One of the company's lead products in clinical trials is an hESC therapy (derived from human stem cells) called GRNOPC1 for spinal cord injury. Geron is also focused on anticancer drug candidate GRN163L, which inhibits telomerase, an enzyme... More

Work at Geron? Share Your Experiences


Click to Rate